市場調查報告書
商品編碼
1084196

口服生技藥品的全球市場:各醫藥品分類,各適應症,各流通管道,各地區,規模,佔有率,展望,機會分析(2022年∼2028年)

Oral Biologics Market, By Drug Class, By Disease Indication, By Distribution channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

由於主要企業的合作,夥伴關係,合併,收購等的策略增加等,促進全球口服生技藥品的市場規模。

本報告提供全球口服生技藥品市場調查,市場概要,市場規模和預測,趨勢,成長要素,阻礙因素,各醫藥品分類、適應症、流通管道、地區的分析,及競爭情形等資訊。

目錄

第1章 調查目的、前提條件

    • 調查目的
    • 假設
    • 簡稱

第2章 市場展望

    • 報告的說明
    • 市場定義和範圍
    • 摘要整理
    • 市場明細:各醫藥品分類
    • 市場明細:各適應症
    • 市場明細:各流通管道
    • 市場明細:各地區
    • Coherent Opportunity Map(COM)

第3章 市場動態,法規,及趨勢分析

    • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析
    • 開發平台分析
    • PEST分析
    • 患者的醫囑遵從性-可注射的生技藥品
    • 法規情境
    • 可注射的生技藥品的限制
    • 流行病學
    • 作用機制-藥丸科技
    • 夥伴關係/合作/收購/契約

第4章 全球口服生技藥品市場:各醫藥品分類(2017年∼2028年)

    • 簡介
    • 市場佔有率分析(2022年及2028年)
    • 與前一年同期比較成長分析(2017年∼2028年)
    • 市場區隔趨勢
    • 胰高血糖素樣肽1(GLP-1)受體激動劑
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)
    • 荷爾蒙
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)
    • 重組酵素
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)
    • 鳥苷酸環化酶-C激動劑
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)
    • 生長抑制素類似體
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)
    • 其他
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)

第5章 全球口服生技藥品市場:各適應症(2017年∼2028年)

    • 簡介
    • 市場佔有率分析(2022年及2028年)
    • 與前一年同期比較成長分析(2017年∼2028年)
    • 市場區隔趨勢
    • 糖尿病
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)
    • 高草酸尿症
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)
    • 肢端肥大症
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)
    • 大腸激躁症(IBS)及慢性特發性便秘(CIC)
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)
    • 其他(發炎性腸道疾病(IBD),甲狀旁腺功能低下症等)
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)

第6章 全球口服生技藥品市場:各流通管道(2017年∼2028年)

    • 簡介
    • 市場佔有率分析(2022年及2028年)
    • 與前一年同期比較成長分析(2017年∼2028年)
    • 市場區隔趨勢
    • 醫院藥局
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)
    • 零售藥局
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)
    • 線上藥局
    • 簡介
    • 市場規模與預測,及與前一年同期比較成長率(2017年∼2028年)

第7章 全球口服生技藥品市場:各地區(2017年∼2028年)

    • 簡介
    • 市場佔有率分析:各地區(2022年及2028年)
    • 與前一年同期比較成長分析,各地區(2017年∼2028年)
    • 北美
    • 市場規模與預測:各醫藥品分類(2017年∼2028年)
    • 市場規模與預測:各適應症(2017年∼2028年)
    • 市場規模與預測:各流通管道(2017年∼2028年)
    • 市場規模與預測:各國(2017年∼2028年)
    • 美國
    • 加拿大
    • 歐洲
    • 市場規模與預測:各醫藥品分類(2017年∼2028年)
    • 市場規模與預測:各適應症(2017年∼2028年)
    • 市場規模與預測:各流通管道(2017年∼2028年)
    • 市場規模與預測:各國(2017年∼2028年)
    • 英國
    • 德國
    • 義大利
    • 法國
    • 西班牙
    • 俄羅斯
    • 其他歐洲
    • 亞太地區
    • 市場規模與預測:各醫藥品分類(2017年∼2028年)
    • 市場規模與預測:各適應症(2017年∼2028年)
    • 市場規模與預測:各流通管道(2017年∼2028年)
    • 市場規模與預測:各國(2017年∼2028年)
    • 中國
    • 印度
    • 日本
    • ASEAN
    • 澳洲
    • 韓國
    • 亞太地區的其他各國
    • 南美
    • 市場規模與預測:各醫藥品分類(2017年∼2028年)
    • 市場規模與預測:各適應症(2017年∼2028年)
    • 市場規模與預測:各流通管道(2017年∼2028年)
    • 市場規模與預測:各國(2017年∼2028年)
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他南美國家
    • 非洲
    • 市場規模與預測:各醫藥品分類(2017年∼2028年)
    • 市場規模與預測:各適應症(2017年∼2028年)
    • 市場規模與預測:各流通管道(2017年∼2028年)
    • 市場規模與預測:各國家/地區(2017年∼2028年)
    • 中非
    • 南非
    • 北非
    • 中東
    • 市場規模與預測:各醫藥品分類(2017年∼2028年)
    • 市場規模與預測:各適應症(2017年∼2028年)
    • 市場規模與預測:各流通管道(2017年∼2028年)
    • 市場規模與預測:各國(2017年∼2028年)
    • GCC
    • 以色列
    • 其他中東

第8章 競爭情形

    • 熱圖分析
    • 企業簡介
    • Novo Nordisk A/S
    • 企業概要
    • 產品系列
    • 主要的發展
    • 財務成果
    • 策略
    • Biocon Limited
    • 企業概要
    • 產品系列
    • 主要的發展
    • 財務成果
    • 策略
    • Oramed Pharmaceuticals, Inc.
    • 企業概要
    • 產品系列
    • 主要的發展
    • 財務成果
    • 策略
    • Rani Therapeutics
    • 企業概要
    • 產品系列
    • 主要的發展
    • 財務成果
    • 策略
    • Entera Bio Ltd.
    • 企業概要
    • 產品系列
    • 主要的發展
    • 財務成果
    • 策略
    • Allergan plc
    • 企業概要
    • 產品系列
    • 主要的發展
    • 財務成果
    • 策略
    • Emisphere Technologies, Inc.
    • 企業概要
    • 產品系列
    • 主要的發展
    • 財務成果
    • 策略
    • Enteris BioPharma, Inc.
    • 企業概要
    • 產品系列
    • 主要的發展
    • 財務成果
    • 策略
    • Chiasma, Inc.
    • 企業概要
    • 產品系列
    • 主要的發展
    • 財務成果
    • 策略
    • Allena Pharmaceuticals, Inc.
    • 企業概要
    • 產品系列
    • 主要的發展
    • 財務成果
    • 策略

第9章 Section

    • 參考文件
    • 調查手法
    • 關於諮詢方式和負責人
目錄
Product Code: CMI989

Biological drugs refer to therapeutic products derived from living organisms or contain components of living organisms. Biological drugs are widely used in the treatment of number of diseases including diabetes, plaque psoriasis, arthritis, Crohn's disease, and ulcerative colitis.

Oral biologics products refer to the biological drugs taken from oral disease indication. Currently, majority of biological drugs are administrated by parenteral route and only guanylate cyclase-c agonist class of drug is approved oral biologics in market.

However, key players in the market are involved in development of orally administered glucagon-like peptide 1 (GLP-1) receptor agonist, recombinant enzyme, somatostatin analogue, and various hormone for different indications.

Market Dynamics

Increasing number of inorganic strategies such as collaborations, partnerships, mergers, and acquisition by key players is a major factor driving growth of the market. For instance, in February 2021, Biocon Limited announced merger with International Diabetes Federation (IDF), an insulin biosimilar company, and the merger focuses on the research and development of Biocon's biologics segment and promote the affordable access of insulin products manufactured by Biocon to the diabetes patients globally.

Key features of the study:

  • This report provides in-depth analysis of the global oral biologics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022 - 2028), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global oral biologics market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, Inc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharma, Inc., Chiasma, Inc. and Allena Pharmaceuticals, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global oral biologics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oral biologics market

Detailed Segmentation:

  • Global Oral Biologics Market, By Drug Class:
  • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
  • Hormone
  • Recombinant Enzyme
  • Guanylate Cyclase-C Agonist
  • Somatostatin Analogue
  • Others
  • Global Oral Biologics Market, By Disease Indication:
  • Diabetes
  • Hyperoxaluria
  • Acromegaly
  • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
  • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)
  • Global Oral Biologics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Oral Biologics Market, By Region:
  • North America

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? U.S.

? Canada

  • Latin America

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? Brazil

? Mexico

? Argentina

? Rest of Latin America

  • Europe

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? Germany

? U.K.

? France

? Italy

? Spain

? Russia

? Rest of Europe

  • Asia Pacific

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? China

? India

? Japan

? Australia

? South Korea

? ASEAN

? Rest of Asia Pacific

  • Middle East

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? GCC

? Israel

? Rest of Middle East

  • Africa

? By Drug Class

? Glucagon-like Peptide 1 (GLP-1) Receptor Agonist

? Hormone

? Recombinant Enzyme

? Guanylate Cyclase-C Agonist

? Somatostatin Analogue

? Others

? By Disease Indication

? Diabetes

? Hyperoxaluria

? Acromegaly

? Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)

? Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism, and Others)

? By Distribution Channel

? Hospital Pharmacies

? Retail Pharmacies

? Online Pharmacies

? By Country

? South Africa

? Central Africa

? North Africa

  • Company Profiles
  • Novo Nordisk A/S *

? Company Overview

? Product Portfolio

? Financial Overview

? Key Highlights

? Market Strategies

  • Biocon Limited
  • Oramed Pharmaceuticals, Inc.
  • Rani Therapeutics
  • Entera Bio Ltd.
  • AbbVie Inc.
  • Enteris BioPharma, Inc.
  • Chiasma, Inc.
  • Allena Pharmaceuticals, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

    • Research Objectives
    • Assumptions
    • Abbreviations

2. Market Purview

    • Report Description
    • Market Definition and Scope
    • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Disease Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
    • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

    • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • PEST Analysis
    • Adherence of Patients- Injectable Biologics
    • Regulatory Scenario
    • Limitations of Injectable Biologics
    • Epidemiology
    • Mechanism of Action- Pill Technology
    • Partnership/Collaboration/Acquisition/Agreement

4. Global Oral Biologics Market, By Drug Class, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
    • Glucagon-like Peptide 1 (GLP-1) Receptor Agonist
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Hormone
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Recombinant Enzyme
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Guanylate Cyclase-C Agonist
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Somatostatin Analogue
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

5. Global Oral Biologics Market, By Disease Indication, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
    • Diabetes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Hyperoxaluria
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Acromegaly
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Irritable Bowel Syndrome (IBS) & Chronic Idiopathic Constipation (CIC)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Others (Inflammatory Bowel Disease (IBD), Hypoparathyroidism and Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Oral Biologics Market, By Distribution Channel, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
    • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
    • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Oral Biologics Market, By Region, 2017 - 2028 (US$ Mn)

    • Introduction
    • Market Share Analysis, By Region, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2028
    • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.S.
    • Canada
    • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of APAC
    • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
    • Central Africa
    • South Africa
    • North Africa
    • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Disease Indication, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East

8. Competitive Landscape

    • Heat Map Analysis
    • Company Profiles
    • Novo Nordisk A/S
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Biocon Limited
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Oramed Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Rani Therapeutics
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Entera Bio Ltd.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Allergan plc
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Emisphere Technologies, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Enteris BioPharma, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Chiasma, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
    • Allena Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Section

    • References
    • Research Methodology
    • About us and Sales Contact